The path is all clear to deliver the next big drug in IBD, raising our PT
Following the recent US IPO, Abivax is well financed to execute its clinical plan with obefazimod with the induction topline results from its phase 3 program in ulcerative colitis expected in Q1 2025. Additionally, we expect the start of a phase 2a study with obefazimod in Crohn's disease to kick o
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.